Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MM`s where very bussy to hold this lower, and try to steel the shares with a stopploss limit last week,. They playing this game, becourse they know this will go hiyer soon.. I think big constitutions will take position in ANX soon. On the Yahoo site ANX 1y Target Est. changed from 4.50 tot $16.. http://finance.yahoo.com/q?s=ANX .When the run realy starts we could move above >$4/5 in no time. Ik think the way up is thin, when buy vollume hits >2/3 mil. Its posible we see this comming week. 8 weeks to go till 1 Sept, but its posible we get the good news sooner than we all think.
So I hold, and buy.. GLTYA..
bought more.. thx..
shake out the weak hands, than run into green..
thats what I think will happen today,.
he could be working on a nice PR.. lol
Big volume on the buy,.
Nice move up today.. 3.20 goooo
Nice, important rally above $3... the way up is open and positive..
More rally`s will folow..
(Rt $3.04)
Adventrx Pharmaceuticals, Inc., (ANX) is trading around $2.85. Adventrx is a biotechnology company, based in California. Shares have traded in a 52 week range between $1.50 to $3.45. The 50 day moving average is $2.49 and the 200 day moving average is $2.28. According to Yahoo Finance, ANX has about $46.5 million in cash and no long term debt. They also have the book value at $1.89. You can see all that data here. Early this year, the U.S. Food and Drug Administration accepted a filing for Exelbine (one of their lead drug candidates), and established a goal date of September 1, 2011 to finish its review of the Exelbine NDA.
Why Adventrx shares could surge higher: Rodman & Renshaw recently raised the price target to $16. The company is expecting an update on its Exelbine NDA around September, which if positive could be a huge catalyst for the shares. If the price target of $16 is reached, investors buying now will gain over 500%.
Palatin Technologies (PTN) has been building a solid base in the 80 to 90 cent range. Palatin is a biotechnology company, based in New Jersey. These shares have traded in a range between 78 cents to $2.70 in the last 52 weeks. The 50 day moving average is 88 cents and the 200 day moving average is $1.14. PTN is developing a diverse range of products for the treatment of sexual dysfunction and other ailments such as congestive heart failure, obesity and metabolic syndrome. Palatin has a partnership agreement with drug giant AstraZeneca (AZN) whereby:
"Palatin is eligible for milestone payments totaling to $145 million, with up to $85 million contingent upon development and regulatory milestones and the balance on achievement of sales targets, together with the payment of royalties on sales of approved products. AstraZeneca assumed responsibility for product commercialization, product discovery and development costs, with both companies contributing scientific expertise in the research collaboration. In addition, Palatin is providing certain research services to AstraZeneca." (Read more about that agreement here).
Although Palatin is not well know amongst most retail investors, famed biotech investors "Deerfield Capital Management" and "BVF, Inc., (Biotechnology Value Fund)" are also heavily invested in this company. You can see that each of these investment companies own a about a 10% stake (for a total of almost 20%) in PTN here. Finally, PTN has at least one more exceptional biotech investor with a major stake of 3,250,000 shares (which is about 9.3% of the company), and that is Jeffrey R. Jay, MD, of Great Point Partners. Jay has an MBA from Harvard as well as an B.A./M.D., (magna cum laude and honors), from Boston University. You can read more about Great Point Partners, and his education and investment experience here. These three very savvy investors are a testament to the tremendous amount of upside in PTN shares.
http://seekingalpha.com/article/276876-5-dirt-cheap-biotech-stocks-poised-to-triple?source=yahoo
Its not a question IF but When bigg rally starts,.
9 weeks till 1 Sept..
Anx partner ? buyout ?..
'If Exelbine is approved in September, the chances for ANX-188 will improve, as well as a chance that a major healthcare company could offer a substantial partnership; or a complete buyout. What may be stopping a large company from making an offer right now',,
http://seekingalpha.com/article/276437-3-small-cap-biotech-companies-with-future-potential
I agree this could happen
We get a nice rally up thats for shure. Its best time for Anx investors up till next 7/8 weeks..
News will explode this stock more,.
Big investors taking position in Anx..
Rally expected soon.. :)
(now 2.85) for later lookback,.
yes, on low vollume.. mm trying to get more and more..
think we rally up soon..
nice day,. dont forget the big vollume when this was above 0.002 this can easy happen again,. When news follows, this can flip up to 0.005 easy.. (imo)
Goodluck,.
we hit .0015-.0017 totday..
Tripples soon if news continous,.
MM`s eating all, becourse they know this could soon tripple..
I think we soon up to .002 there was lot activity on the buy last jump.. Forcast for this company is great,. Every day could be a nice PR day,.
Good luck, hold it.. buy if you yust as I believe this is an real penny worth,.
First news in 2 weeks, imo more in next days,. I think the company is growing big on all the items they sell..
I thinking to buy an detector my self..
this is an new nice deal, that yustifies an nice rally up...
great news,.. afther marked,. I think we will see more soon.
this is making $ and do a good job,. for those people over there..
Apr 13, 2011 18:36 ETUniversal Detection Technology Enters Into a Distribution Agreement for Its Radiation Detection Product Line in Japan and Singapore
APP Systems Will Market UNDT's Radiation Detection Equipment in Japan and Singapore
LOS ANGELES, CA--(Marketwire - April 13, 2011) - Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies that protect against biological, chemical, and radiological threats, announced today that it has signed an agreement with APP System Services (APP). APP will market UNDT's radiation detection devices in Japan and Singapore.
APP is a premier sales and service provider for high technology products, in biotech, environmental and defense industries. APP serves both the private and government sectors.
The most recent assessment of the radiation level in Japan is that it is officially equal to Chernobyl. Officials with the company that operates Japan's tsunami-stricken nuclear plant say radioactive contamination in groundwater underneath a reactor has been measured at 10,000 times the government health standard. A spokesman for plant operator Tokyo Electric Power Co says the company doesn't believe any drinking water supply is affected. Contaminated water has been pooling at the Fukushima Daiichi nuclear power complex since it was damaged by the devastating earthquake and tsunami. It has already leaked into the ocean.
The Environmental Protection Agency (EPA) reported today that low levels of radiation have turned up in milk samples from two West Coast states. The EPA and the Food and Drug Administration said that radiation was found in a March 25 milk sample from Spokane, Washington. The California Department of Public Health said on its website that a similar result was found March 28 at a dairy in San Luis Obispo County.
"Through our agreement with APP System Services we plan to make our radiation detection products available to a broad market in Japan and Singapore," said Jacques Tizabi UNDT's Chairman and CEO. "APP will use its sales force to market UNDT's radiation detection devices to both the government and private sectors. While there has been a rush by consumers to quickly purchase hand-held dosimeters, most of which are currently in very short supply by us and other suppliers, there continues to be an interest from institutional customers for more sophisticated detection equipment which we hope to be able to provide not necessarily in the immediate present, but throughout the length of this crisis," he added.
For more information please visit www.udetection.com or email info@udetection.com.
>Watch livestream Japan..
http://www.msnbc.msn.com/id/21134540/vp/42473623#42474234
>Watch this movie detection in action in japan,.
see how inportant UNDT can be for Japan,. detection in action !
If mm have there shares this will rally up...
think company updates sales soon,.
I @ buy, when they trying to get this down..
The only reasen mm sell, is to get more at lower prizes..
mm playing games till the have enough shares for big rally... they know great news soon.
Its for sure, products sold big now..
next week,. big rally here,. this is getting hot.. you see big activity sinds 2 weeks in this stock.. News can hit this into cents..
this could be a goldmine,. 1 week no news,. and I am sure there is something happening,.
bought some,. could be nice if UNDT gets big orders from all over the world.. thanks to internet..
grtz.. succes.. leon
No delisting first 6 months,..
24-Jan-2011
Other Events
Item 8.01. Other Events.
On January 19, 2011, Poniard Pharmaceuticals, Inc. (the "Company") received a letter from The Nasdaq Stock Market notifying the Company that it has been granted an additional 180 calendar day period, or until July 18, 2011, to regain compliance with the minimum $1.00 bid price requirement. The additional time period was granted based on the Company's meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the bid price requirement, and the Company's written notice to Nasdaq of its intention to cure the deficiency during the additional compliance period by effecting a reverse stock split, if necessary. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during the additional time period. Nasdaq may, in its discretion, require the Company's common stock to maintain a closing bid price of at least $1.00 for a period in excess of ten consecutive trading days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. If the Company does not demonstrate compliance by July 18, 2011, it will receive written notification from the Nasdaq Listing Qualifications Staff that the Company's common stock will be delisted. At that time, the Company may appeal the determination to a Nasdaq Hearings Panel and provide a plan to regain compliance to the Panel.
So they are in time(line)... every new day, new news chances..
AH would be nice,.. (eom)
Anx has an very low marked cap.. and for every share $2,- in cash in hands, thats the difference at this time.. We need different green lights in the near future.. Anx is now closer than it ever was, and look wat pp/marked cap was at that time,.. (year(s)ago)
the pp range from now till all is accepted could be:
$2.60 >>> $20 >> $40 >> $80 ???????
the question is when to buy,.. (now or later) If all gets green and accepted in the near future..
I bought a lot @1.90 and hold them long..
Succes,..
Grtz.. leon
Also keep an eye on ANX the comming days,..
Grtz.. leon
The first step is de FDA.. this comming days,.. for ANX first product to the marked.. I expect an positive reaction on the pp when the first step is positive.. !!
ADVENTRX Submits Exelbine(TM) New Drug Application
SAN DIEGO, Nov. 3, 2010 /PRNewswire via COMTEX/ --
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.
"Our Exelbine submission includes twelve months of site-specific stability data from our intended commercial manufacturer, which fulfills a request communicated to us by the FDA earlier this year. We believe this submission will be accepted for review in early 2011 and we look forward to working with the Agency toward our first product approval," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
ADVENTRX retains exclusive worldwide rights to Exelbine, other than in China, Hong Kong, Macau and Taiwan. In March 2010, the FDA conditionally accepted "Exelbine" as the proposed proprietary name for ANX-530. In October 2010, patent claims related to Exelbine were allowed by the United States Patent and Trademark Office. These patent claims, when issued, will extend into 2024.
ADVENTRX is seeking approval of Exelbine for the same indications as Navelbine(R), a branded formulation of vinorelbine, including non-small cell lung cancer. ADVENTRX submitted the NDA as a 505(b)(2) application that relies in part on the FDA's findings of safety and effectiveness of a reference drug. The Company's 505(b)(2) NDA submission includes data from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence of Exelbine and Navelbine, the reference drug. In this clinical bioequivalence study, Exelbine and the reference drug were determined by ADVENTRX to be bioequivalent.
the Second step.. second product:
ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study
SAN DIEGO, Dec. 15, 2010 /PRNewswire via COMTEX/ --
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) to schedule a meeting for the purpose of discussing its product candidate ANX-514 (docetaxel emulsion for injection). The FDA is expected to set the meeting date within 60 days of receiving the request from ADVENTRX.
"We have performed an extensive analysis of the data from our bioequivalence study of ANX-514, as well as on results from other trials using Taxotere(R), and plan to discuss our findings at the meeting," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
"Based in part on the substantial variability observed with Taxotere as reported in the literature, we believe the transitory elevations in total docetaxel concentrations for ANX-514 do not affect adversely its safety or efficacy relative to Taxotere. However, the FDA is the final arbiter of safety and efficacy and, following our meeting, we will provide an update on the next steps and requirements for advancing ANX514 toward an NDA submission," Mr. Culley continued.
Grtz.. leon
I feel it every time, lol. bought more low..
I know the games MM`s play.. on good stocks.. dump and buy low..!
I think we rally up soon...
mm`s make $ to shake trees,.. and then up..
Hope to get some news from ANX... eom.
youre right, but this will be a inportant step for a great future..
Grtz.. leon
nice website.. all in in one vieuw.. thanks..
grtz.. leon
ANX Facts 2011 >>
ANX has approximately 15 million shares outstanding and a market cap of approximately $44million
As of September 30, 2010, ANX has $29 Million in cash ($2,- a share), and $0 in long term debt (also a very low monthly burn rate).
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-SECText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDA5NTAxMjMtMTAtMTAyNDU3L3htbC9zdWJkb2N1bWVudC8xL3BhZ2UvNA%3d%3d
-ANX is audited by J.H. Cohen
-ANX received two rounds of financing in 2010 in exchange for stock options and warrants
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1372707&highlight=
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1423666&highlight=
ANX has a patent on it's technology in their drug ANX-530
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1479583&highlight=
ANX met with FDA to assure success of it's NDA filing of ANX-530
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1406669&highlight=
ANX submits NDA for ANX-530 to FDA and anticipates decision in early January 2011 (1 week!)
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1490940&highlight=
ANX sets meeting to discuss its potential multi-billion dollar drug, ANX-514 in mid-February 2011
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1507944&highlight=
Carl Icahn is one of the largest institutional investors of ANX
http://stockpickr.com/pro/portfolio/Carl-Icahn/?page=3
Icahn has a rep on ANX BOD that specializes in biotech M&A
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1382400&highlight=
ANX hires firm that specializes in M&A to look for opportunities
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=1458492&highlight=
ANX currently has large short position on extremely small float (type in "ANX"):
http://www.amex.com/amextrader/tradingData/amexShortInt/AmexShortInterest.jsp
Just the FACTS Folks!
thx to aferrara01 (on Y.Board) Nr.1 post..
grtz. leon